dichlororibofuranosylbenzimidazole has been researched along with Bone Loss, Osteoclastic in 1 studies
Dichlororibofuranosylbenzimidazole: An RNA polymerase II transcriptional inhibitor. This compound terminates transcription prematurely by selective inhibition of RNA synthesis. It is used in research to study underlying mechanisms of cellular regulation.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yamaguchi, M | 1 |
| Uchiyama, S | 1 |
1 other study available for dichlororibofuranosylbenzimidazole and Bone Loss, Osteoclastic
| Article | Year |
|---|---|
Receptor activator of NF-kappaB ligand-stimulated osteoclastogenesis in mouse marrow culture is suppressed by zinc in vitro.
Topics: Animals; Bone Marrow Cells; Bone Resorption; Carrier Proteins; Cells, Cultured; Cycloheximide; Dichl | 2004 |